Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Evolva announces $26.7 million award from the United States Defense Threat Reduction Agency

8th November 2006 -- Evolva Biotech SA (Allschwil, Switzerland) a biotech company focused on the discovery and development of drugs based on genetic chemistry approaches today announced that it has received a $26.7 million award from the United States Defense Threat Reduction Agency (DTRA) for the discovery and development of therapeutics that improve the ability of humans to resist diverse pathogens, in particular potential biowarfare or bioterrorism agents.

Evolva will use the award over a five year period to discover and develop compounds through to the filing of Investigational New Drug applications. Evolva will conduct this program in collaboration with Isconova AB (Uppsala, Sweden).

Neil Goldsmith, Managing Director of Evolva, said “The DTRA award shows the potential applicability of our genetic chemistry technologies to a further therapeutic area. It allows us to build a pipeline of compounds with immunomodulatory and other effects that can assist humans resist pathogens and other diseases, including as yet uncharacterised threats. Isconova is providing invaluable knowledge of relevant targets, structures and disease biology”.

About Evolva. Evolva evolves small molecule drugs using massively combinatorial gene libraries that drive chemistry rich pathways. Its Watchmaker® technology platform replicates, on an industrial basis, the ability of nature to evolve molecules with exquisite “design”, but with the evolution directly aimed at making functional drugs – HIV blockers, anti-obesity compounds etc. Watchmaker® can create, optimize and manufacture molecules that are outside the scope of the traditional synthetic approaches of the industry. For more information see

About the Defense Threat Reduction Agency (DTRA). The Defense Threat Reduction Agency (DTRA) safeguards America and its allies from weapons of mass destruction by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. This Department of Defense agency is located at Fort Belvoir, Virginia, and operates field offices worldwide. For further information see

Publisher Contact Information:

Evolva SA
+41 (0)61 485 2000

Company profile of Evolva SA
Past press releases of Evolva SA.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.